Advertisement

Palliative Care for Patients With Cancer and Kidney Disease

      Patients with cancer and kidney disease experience a range of symptoms that impact their quality of life. Pain, fatigue, decreased appetite, and depression are all common in this population. Kidney palliative care is patient-centered medical care focused on reducing symptoms and defining individualized goals of care for patients and their families. Pharmacologic management of pain in patients with cancer and kidney disease requires recognition of the type of pain, its cause, and the risks and benefits of different medication classes. This review describes basic symptom management options as well as considerations for discussing goals of care, prognosis, and end of life.

      Graphical abstract

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Advances in Chronic Kidney Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rosner M.H.
        • Perazella M.A.
        Acute kidney injury in patients with cancer.
        N Engl J Med. 2017; 376: 1770-1781
        • Humphreys B.D.
        • Soiffer R.J.
        • Magee C.C.
        Renal failure associated with cancer and its treatment: an update.
        J Am Soc Nephrol. 2005; 16: 151-161
        • Gelfand S.L.
        • Schell J.O.
        • Eneanya N.D.
        Palliative care in nephrology: the Work and the Workforce.
        Adv Chronic Kidney Dis. 2020; 27: 350-355
        • Abdel-Kader K.
        • Unruh M.L.
        • Weisbord S.D.
        Symptom burden, depression, and quality of life in chronic and end-stage kidney disease.
        Clin J Am Soc Nephrol. 2009; 4: 1057-1064
        • Bubis L.D.
        • Davis L.
        • Mahar A.
        • et al.
        Symptom burden in the first Year after cancer Diagnosis: an Analysis of patient-Reported outcomes.
        J Clin Oncol. 2018; 36: 1103-1111
        • Davison S.N.
        • Koncicki H.
        • Brennan F.
        Pain in chronic kidney disease: a scoping review.
        Semin Dial. 2014; 27: 188-204
        • Weisbord S.D.
        • Fried L.F.
        • Mor M.K.
        • et al.
        Renal provider recognition of symptoms in patients on maintenance hemodialysis.
        Clin J Am Soc Nephrol. 2007; 2: 960-967
        • Laugsand E.A.
        • Sprangers M.A.
        • Bjordal K.
        • Skorpen F.
        • Kaasa S.
        • Klepstad P.
        Health care providers underestimate symptom intensities of cancer patients: a multicenter European study.
        Health Qual Life Outcomes. 2010; 8: 104
        • Koncicki H.M.
        • Unruh M.
        • Schell J.O.
        Pain management in CKD: a guide for nephrology providers.
        Am J Kidney Dis. 2017; 69: 451-460
        • Ravel V.
        • Ahmadi S.F.
        • Streja E.
        • et al.
        Pain and kidney function decline and mortality: a cohort study of US veterans.
        Am J Kidney Dis. 2016; 68: 240-246
        • Davison S.N.
        • Tupala B.
        • Wasylynuk B.A.
        • Siu V.
        • Sinnarajah A.
        • Triscott J.
        Recommendations for the care receiving conservative kidney management.
        Clin J Am Soc Nephrol. 2019; 14: 626-634
        • Barakzoy A.S.
        • Moss A.H.
        Efficacy of the world health organization analgesic ladder to treat pain in end-stage renal disease.
        J Am Soc Nephrol. 2006; 17: 3198-3203
        • Kimmel P.L.
        • Fwu C.W.
        • Abbott K.C.
        • Eggers A.W.
        • Kline P.P.
        • Eggers P.W.
        Opioid Prescription, morbidity, and mortality in United States dialysis patients.
        J Am Soc Nephrol. 2017; 28: 3658-3670
        • Cuomo A.
        • Bimonte S.
        • Forte C.A.
        • Botti G.
        • Cascella M.
        Multimodal approaches and tailored therapies for pain management: the trolley analgesic model.
        J Pain Res. 2019; 12: 711-714
        • Mercadante S.
        Opioid analgesics adverse effects: the other side of the Coin.
        Curr Pharm Des. 2019; 25: 3197-3202
        • Ishida J.H.
        • McCulloch C.E.
        • Steinman M.A.
        • Grimes B.A.
        • Johansen K.L.
        Opioid analgesics and adverse outcomes among hemodialysis patients.
        Clin J Am Soc Nephrol. 2018; 13: 746-753
        • Gelfand S.L.
        • Juurlink D.N.
        Pain region. NephMadness.
        • Chino F.L.
        • Kamal A.
        • Chino J.P.
        Opioid-associated deaths in patients with cancer: a population study of the opioid epidemic over the past 10 years.
        J Clin Oncol. 2018; 36: 230
        • Mueller S.R.
        • Walley A.Y.
        • Calcaterra S.L.
        • Glanz J.M.
        • Binswanger I.A.
        A review of opioid Overdose prevention and naloxone prescribing: Implications for Translating community Programming into clinical Practice.
        Subst Abus. 2015; 36: 240-253
        • Haroutiunian S.
        • Drennan D.A.
        • Lipman A.G.
        Topical NSAID therapy for musculoskeletal pain.
        Pain Med. 2010; 11: 535-549
        • Dreischulte T.
        • Morales D.R.
        • Bell S.
        • Guthrie B.
        Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury.
        Kidney Int. 2015; 88: 396-403
        • Sriperumbuduri S.
        • Hiremath S.
        The case for cautious consumption: NSAIDs in chronic kidney disease.
        Curr Opin Nephrol Hypertens. 2019; 28: 163-170
        • Baker M.
        • Perazella M.A.
        NSAIDs in CKD: are they Safe?.
        Am J Kidney Dis. 2020; 76: 546-557
        • Guthrie B.
        Can NSAIDs be used safely for analgesia in patients with CKD?.
        CON Kidney360. 2020; 1: 1189-1191
        • Lussier D.
        • Huskey A.G.
        • Portenoy R.K.
        Adjuvant analgesics in cancer pain management.
        Oncologist. 2004; 9: 571-591
        • Quirk K.
        • Smith M.A.
        Acetaminophen in patients receiving strong opioids for cancer pain.
        J Pain Palliat Care Pharmacother. 2020; 34: 197-202
        • American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons
        Pharmacological management of persistent pain in older persons.
        J Am Geriatr Soc. 2009; 57: 1331-1346
        • Rakoski M.
        • Goyal P.
        • Spencer-Safier M.
        • Weissman J.
        • Mohr G.
        • Volk M.
        Pain management in patients with cirrhosis.
        Clin Liver Dis. 2018; 11: 135-140
      1. Drug information for infants, children, and adults.
        • Bennett M.I.
        Effectiveness of antiepileptic or antidepressant drugs when added to opioids for cancer pain: systematic review.
        Palliat Med. 2011; 25: 553-559
        • Finnerup N.B.
        • Sindrup S.H.
        • Jensen T.S.
        The evidence for pharmacological treatment of neuropathic pain.
        Pain. 2010; 150: 573-581
        • Obata H.
        Analgesic Mechanisms of antidepressants for neuropathic pain.
        Int J Mol Sci. 2017; 18: 2483
        • Backonja M.
        • Beydoun A.
        • Edwards K.R.
        • et al.
        Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
        JAMA. 1998; 280: 1831-1836
        • Raouf M.
        • Atkinson T.J.
        • Crumb M.W.
        • Fudin J.
        Rational dosing of gabapentin and pregabalin in chronic kidney disease.
        J Pain Res. 2017; 10: 275-278
        • Gelfand S.L.
        • Scherer J.S.
        • Koncicki H.M.
        Kidney supportive care: Core Curriculum 2020.
        Am J Kidney Dis. 2020; 75: 793-806
        • Mercadante S.L.
        • Berchovich M.
        • Casuccio A.
        • Fulfaro F.
        • Mangione S.
        A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients.
        Am J Hosp Palliat Care. 2007; 24: 13-19
        • Scott S.C.
        • Pennell N.A.
        Early use of systemic corticosteroids in patients with advanced NSCLC treated with Nivolumab.
        J Thorac Oncol. 2018; 13: 1771-1775
        • Hwang S.S.
        • Chang V.T.
        • Rue M.
        • Kasimis B.
        Multidimensional independent predictors of cancer-related fatigue.
        J Pain Symptom Manage. 2003; 26: 604-614
        • Crawford J.
        • Cella D.
        • Cleeland C.S.
        • et al.
        Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
        Cancer. 2002; 95: 888-895
        • Leyland-Jones B.
        • Bondarenko I.
        • Nemsadze G.
        • et al.
        A randomized, open-label, multicenter, phase III study of epoetin alfa versus best standard of care in anemic patients with metastatic breast cancer receiving standard chemotherapy.
        J Clin Oncol. 2016; 34: 1197-1207
        • Bohlius J.
        • Bohlke K.
        • Castelli R.
        • et al.
        Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical Practice Guideline update.
        J Clin Oncol. 2019; 37: 1336-1351
        • Tarricone R.
        • Ricca G.
        • Nyanzi-Wakholi B.
        • Medina-Lara A.
        Impact of cancer anorexia-cachexia syndrome on health-related quality of life and resource utilisation: a systematic review.
        Crit Rev Oncol Hematol. 2016; 99: 49-62
        • Theobald D.E.
        • Kirsh K.L.
        • Holtsclaw E.
        • Donaghy K.
        • Passik S.D.
        An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
        J Pain Symptom Manag. 2002; 23: 442-447
        • Aisner J.
        • Parnes H.
        • Tait N.
        • et al.
        Appetite stimulation and weight gain with megestrol acetate.
        Semin Oncol. 1990; 17: 2-7
        • Loprinzi C.L.
        • Kugler J.W.
        • Sloan J.A.
        • et al.
        Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia.
        J Clin Oncol. 1999; 17: 3299-3306
        • Naing A.
        • Dalal S.
        • Abdelrahim M.
        • et al.
        Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.
        Support Care Cancer. 2015; 23: 2649-2654
        • Jatoi A.
        • Windschitl H.E.
        • Loprinzi C.L.
        • et al.
        Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.
        J Clin Oncol. 2002; 20: 567-573
        • Navari R.M.
        • Einhorn L.H.
        • Passik S.D.
        • et al.
        A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
        Support Care Cancer. 2005; 13: 529-534
        • Garcia J.M.
        • Li H.
        • Mann D.
        • et al.
        Hypogonadism in male patients with cancer.
        Cancer. 2006; 106: 2583-2591
        • Thirumavalavan N.
        • Wilken N.A.
        • Ramasamy R.
        Hypogonadism and renal failure: an update.
        Indian J Urol. 2015; 31: 89-93
        • Mohamed O.
        • Freundlich R.E.
        • Dakik H.K.
        • et al.
        The quantitative ADAM questionnaire: a new tool in quantifying the severity of hypogonadism.
        Int J Impot Res. 2010; 22: 20-24
        • Peuckmann V.
        • Elsner F.
        • Krumm N.
        • Trottenberg P.
        • Radbruch L.
        Pharmacological treatments for fatigue associated with palliative care.
        Cochrane Database Syst Rev. 2010; : CD006788
        • Hedayati S.S.
        • Yalamanchili V.
        • Finkelstein F.O.
        A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease.
        Kidney Int. 2012; 81: 247-255
        • Ng C.G.
        • Boks M.P.
        • Zainal N.Z.
        • De Wit N.J.
        The prevalence and pharmacotherapy of depression in cancer patients.
        J Affect Disord. 2011; 131: 1-7
        • Gradalski T.
        Edema of advanced cancer: prevalence, etiology, and conservative management: a single hospice cross-sectional study.
        . 2019; 57: 311-318
        • Paladino J.
        • Lakin J.R.
        • Sanders J.J.
        Communication strategies for sharing prognostic information with patients: beyond survival statistics.
        JAMA. 2019; 322: 1345-1346
        • Davison S.
        End of life care preferences and needs: perceptions of patients with chronic kidney disease.
        Clin J Am Soc Nephrol. 2010; 5: 195-204
        • Lim W.H.
        • Au E.
        • Krishnan A.
        • Wong G.
        Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?.
        Transpl Int. 2019; 32: 1223-1240
        • Perazella M.A.
        • Sprangers B.
        AKI in patients recieiving immune checkpoint inhibitors.
        Clin J Am Soc Nephrol. 2019; 14: 1077-1079
        • Grubbs V.
        • Moss A.H.
        • Cohen L.M.
        • et al.
        A palliative approach to dialysis care: a patient-centered transition to the end of life.
        Clin J Am Soc Nephrol. 2014; 9: 2203-2209
        • Schell J.O.
        • Johnson D.S.
        Challenges with providing hospice care for patients undergoing long-term dialysis.
        Clin J Am Soc Nephrol. 2021; 16: 473-475